Clinical Trial vs Hospital Reality: Vetting AI Radiology Claims

A vendor tells you their AI detects intracranial hemorrhage at 99.2% accuracy. You deploy it in your ER. Three months later, your radiologists report it misses subtle subdural bleeds on elderly patients with prior head trauma. What happened?

You've hit the clinical trial-to-deployment gap.

Clinical trials—especially retrospective ones—are built on curated data where cases are selected, reviewed by board-certified radiologists, and analyzed under controlled conditions. Real hospital imaging is messier: incomplete prior studies, protocol deviations, varied hardware, clinician shortcuts, incidental findings, patient populations that don't match the trial cohort. A model that achieves 99.2% accuracy on a clean retrospective dataset can drop to 87% on real hospital data because the real data is fundamentally different.

This isn't vendor deception. It's a natural consequence of how clinical AI is validated. But it's also why hospitals often report disappointing performance from expensive AI deployments. You need to understand the gap, audit vendor claims like a clinical researcher, and pilot test on your actual data before betting on accuracy promises.

The Curation Problem: Why Clinical Trials Optimize for Accuracy

Retrospective clinical trials are the gold standard for regulatory approval, but they're optimized for accuracy measurement, not real-world deployment. Here's why.

Selection bias starts before imaging. Most published studies recruit from academic medical centers with high case volumes of the condition in question. If you're validating a model to detect tension pneumothorax, you source cases from trauma centers and large urban EDs where pneumothorax prevalence is 2–4%, not from the average community hospital where it's 0.1%. Your validation cohort is enriched for the pathology you want to detect, which inflates sensitivity and positive predictive value. A model trained on data where 15% of images contain the target finding will report much higher accuracy than one used in a hospital where the prevalence is 2%.

Radiologist expertise is standardized in trials, not in deployment. Most published AI validation studies use readings from board-certified subspecialists—often radiologists with 10+ years of experience in the specific anatomy. Your hospital's night-shift radiologist with 3 years of experience will read differently. They'll miss incidental findings, misinterpret protocols from other hospitals, spend less time on complex cases. The model was validated against expert consensus, not average clinical practice.

Prior studies are complete in trials, fragmented in reality. A retrospective trial selects cases with full imaging history—prior CTs, MRIs, X-rays are available for comparison. Real hospitals have incomplete histories: referrals come without priors, urgent cases are read without waiting for historical imaging, patients switch health systems and records don't transfer. grad-cam heatmaps and attention mechanisms in modern AI models rely heavily on prior-to-current comparison. Miss the priors, and the model's confidence and accuracy both degrade.

Real Hospital Data: Where Accuracy Drops

Deployment introduces variables no clinical trial controls for.

dicom protocol variation is massive in practice. Different vendors (GE, Siemens, Philips) encode DICOM metadata differently. Different hospitals use different reconstruction algorithms, slice thicknesses, and imaging protocols for the same anatomy. The official DICOM standard allows flexibility in image structure encoding, which means a single finding can be represented differently across systems. Models trained on a homogeneous dataset of images from a single vendor's equipment often don't generalize to real-world multi-vendor environments. Fractify handles this by training on DICOM datasets from 7+ different imaging vendors and hospital systems—but many vendors don't.

clinical workflow doesn't match the trial protocol. The study assumes radiologists will read images in quiet, distraction-free conditions, spend 3–5 minutes per case, refer to structured reporting templates, and escalate critical findings through a formal workflow. Real hospitals: radiologists are reading 30 cases per hour under time pressure, skipping structured reports when busy, escalating findings verbally to whoever's available. If the AI model was validated on reads that take 5 minutes per case, what happens when a real radiologist spends 90 seconds? They'll use less of the model's output, trust it less, override it more frequently, and the measured accuracy will be lower.

Patient populations shift, and so does performance. Most published AI studies validate on cohorts that are 65–75% male, 60+ years old, with clearly defined pathology. Real hospital populations vary: your pediatric cases have different anatomy; your urgent-care referrals are younger and healthier; your international patients may have imaging protocols from non-English-speaking countries. A model validated on adult trauma data will perform differently on a pediatric cohort or a geriatric population with multiple comorbidities and prior surgeries.

How to Vet AI Radiology Claims Like a Clinical Researcher

Before procurement, apply these audits to vendor claims.

Assess the study design. Retrospective studies on curated datasets are useful for regulatory approval, but they're not predictive of deployment performance. Prospective studies where the AI reads cases in real clinical time, with real radiologists making real clinical decisions, are far more informative. Ask: Was this a retrospective or prospective study? If retrospective, what were the selection criteria? Were cases selected because they were easy (healthy controls) or because they were known positives? Did radiologists know they were being evaluated (Hawthorne effect)? Were consensus reads used, or single-reader ground truth?

Characterize the data. Get specifics on the training and validation cohorts: How many cases? What age/gender/comorbidity distribution? Single hospital system or multi-center? What imaging vendors and protocols? What was the prevalence of the target finding? If a vendor trained on a dataset that's 80% from academic centers and 20% from community hospitals, but you're a community hospital, performance will be different for you. Ask: What's the vendor's data diversity score? Have they validated on hospitals that look like yours?

Demand external validation. Internal validation (testing on data the model was trained on) always shows inflated accuracy. Independent external validation on a separate hospital system with separate radiologists is the only honest accuracy measure. Many vendors skip this because it costs money and invariably shows lower numbers. If a vendor can't produce external validation results, that's a red flag. Fractify underwent independent external validation by radiologists at 3 hospitals outside our original training sites—we report 97.9% accuracy on brain mri tumor detection and 97.7% on bone fracture detection because those numbers come from real-world hospital tests, not internal retrospective studies.

Ask what happens with edge cases. How does the model perform on:

• Patients with prior surgery or hardware (pacemakers, shunts, spinal fusion)?
• Poor-quality images (motion artifact, patient obesity, metal scatter)?
• Incidental findings outside the model's training domain?
• Cases where the imaging protocol deviates from standard (unconventional slice thickness, non-standard reconstructions)?

Most vendors have no data on these scenarios because clinical trials exclude them. If vendor can't answer, you'll discover the gaps at 2 AM when your on-call radiologist tries to use the model on a post-stroke patient with a ferromagnetic aneurysm clip.

Red Flags That Should Stop Your Procurement

Before signing a contract, watch for these warnings.

1. Vendor claims accuracy only on their internal dataset. If they've never validated on external data, they're hiding performance degradation. "We tested on 50,000 cases from our partner hospitals" sounds reassuring until you learn all 50,000 came from a single large academic center. Ask: Has any third-party hospital independently validated your model?

2. Accuracy claims without specifying the patient population or prevalence. "Our AI detects aortic dissection at 96% sensitivity" is meaningless without knowing: Was this on a cohort that's 50% aortic dissection cases? Was it on 100 carefully selected cases or 10,000 unselected cases? A model can report 96% sensitivity on a highly selected dataset and 70% sensitivity on unselected cases.

3. No mention of explainability or failure modes. A responsible AI vendor will tell you: "Our model fails on these types of images: dense breast tissue, artifacts from cardiac pacing, non-standard slice thickness." If a vendor claims near-perfect accuracy with no caveats, they either haven't tested thoroughly or they're not being honest about limitations.

4. Promises of "plug-and-play" integration with zero workflow change. This is impossible. Every AI deployment changes radiologist workflow. If the vendor claims their model requires zero training, zero process changes, and zero oversight, they're not accounting for real deployment.

Fractify's Real-World Validation Approach

When we built Fractify at Databoost Sdn Bhd, we started with the premise that published accuracy numbers mean nothing until validated in a real hospital. Our training pipeline included DICOM data from 7 different imaging hardware vendors, 6 hospital systems across 3 countries, and 2,000+ practicing radiologists of varying experience levels. We don't train on curated, high-quality datasets; we train on the messy, real data that hospitals have.

Our brain MRI tumor detection model: 97.9% accuracy. But that's not an internal validation number. It's from a prospective trial where radiologists at 3 independent hospitals (not our training centers) ran the model on cases as they arrived in real clinical time, and we measured detection rates against their consensus reads. Our bone fracture detection: 97.7% accuracy, same methodology. These numbers are lower than many vendors claim because we measure them honestly—on real hospital data with real radiologist workflows, not on retrospective, curated datasets.

We also built Fractify with transparency about limitations. The model performs best on standard protocols from major vendors (GE, Siemens, Philips). It requires prior studies for confidence scoring on intracranial findings. It has lower sensitivity on patients with extensive prior surgery or hardware. We tell customers this upfront because it's true, and they can plan for it.

Implementing AI When You Know the Gap Exists

Understanding the clinical trial-to-deployment gap changes how you should implement AI.

Start with a pilot, not a full rollout. Deploy the model on 5–10% of cases (or a single department) for 4–8 weeks. Measure actual performance: What's the sensitivity and specificity on your real data? How do your radiologists use it? What overrides occur, and why? This is where you discover the gap between vendor claims and your reality. Don't assume 97.9% accuracy means 97.9% for you.

Measure against your own ground truth, not the vendor's claims. After your radiologists have used the model for 4 weeks, run a retrospective assessment: randomly select 100–200 cases where the model and a radiologist disagreed, and have a second independent radiologist adjudicate. This gives you honest accuracy on your population, your protocols, your radiologists' workflows.

Account for workflow integration. The model's accuracy on static cases in a lab is different from its accuracy when integrated into a busy clinical workflow. When radiologists are reading 30 cases per hour, will they trust the model's output? Will they spend time interpreting the explanation (heatmaps, confidence scores) or will they ignore it? Will they integrate it into their PACS workflow or work around it? These are operational questions, not technical ones, and they dominate real-world accuracy.

I'd argue that the clinical trial-to-deployment gap is less a problem with AI vendors and more a problem with how hospitals evaluate AI. If you approach vendor claims with the same skepticism you'd apply to a clinical trial—asking hard questions about study design, external validation, and population characterization—you'll avoid most disappointments.

Honestly: When Not to Deploy

There are scenarios where I wouldn't recommend deploying a given AI model, even if the vendor's numbers look good. If your hospital is a small rural facility with highly non-standard imaging protocols and minimal prior-study availability, many AI models trained on multi-center data will underperform. If your radiologists are stretched thin and don't have time to learn a new tool or validate its recommendations, deployment will fail even if the model is technically accurate. If your PACS system is legacy and doesn't have modern HL7/FHIR integration, you can't implement the workflow changes needed to use AI effectively. These are honest limitations, and a responsible hospital should know them before procurement.

The clinical trial-to-deployment gap isn't a bug in AI; it's a feature of how clinical validation works. Understanding it, auditing vendor claims against it, and piloting on real data before full deployment will save you months of frustration and millions in wasted technology spend.